Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 5/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14161428 | 0.97 | EGLN2 (0.38) | AKT1AKT2EGLN2PGRGPR119 | |
| SCHEMBL9923372 | 0.95 | AKT1 (0.41) | AKT1EGLN2PGRGPR119DRD2 | |
| SCHEMBL1905128 | 0.87 | AKT1 (0.40) | AKT1AKT2DRD2PDE2A | |
| SCHEMBL3052055 | 0.86 | EGLN2 (0.38) | EGLN2PGRGPR119DRD2ABCB1 | |
| SCHEMBL15255661 | 0.85 | PGR (0.39) | EGLN2PGRGPR119DRD2ABCB1 | |
| SCHEMBL538971 | 0.85 | PGR (0.39) | EGLN2PGRGPR119DRD2ABCB1 | |
| SCHEMBL13152804 | 0.85 | PGR (0.39) | EGLN2PGRGPR119DRD2ABCB1 | |
| SCHEMBL1534790 | 0.85 | AKT1 (0.44) | AKT1AKT2DRD2PDE2A | |
| SCHEMBL14161397 | 0.83 | AKT1 (0.42) | AKT1AKT2DRD2PDE2A | |
| SCHEMBL27979153 | 0.82 | AKT1 (0.41) | AKT1AKT2DRD2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103596957-B | Imidazopyridazines as AKT kinase inhibitors | 拜耳知识产权有限责任公司 | 2016-12-07 | — | — | CN | disclosed |
| CN-104066735-B | Substituted imidazopyrazines as AKT kinase inhibitors | 拜耳知识产权有限责任公司 | 2016-08-31 | — | — | CN | disclosed |
| EP-2593451-B1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AND -PYRIDINES | BAYER IP GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-8975265-B2 | Substituted imidazo[1,2-a]pyrimidines and —pyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-10 | — | — | US | disclosed |
| CN-104066735-A | Substituted imidazopyrazines as AKT kinase inhibitors | BAYER IP GMBH | 2014-09-24 | — | — | CN | disclosed |
| US-8691825-B2 | Inhibitors of AKT activity | MERCK SHARP & DOHME CORP. (US) | 2014-04-08 | — | — | US | disclosed |
| CN-103596957-A | Imidazopyridazines as AKT kinase inhibitors | BAYER IP GMBH | 2014-02-19 | — | — | CN | disclosed |
| US-20130287763-A1 | COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2013-10-31 | — | — | US | disclosed |
| CN-101600706-B | Inhibitors of akt activity | MERCK SHARP & DOHME | 2013-10-16 | — | — | CN | disclosed |
| US-8536193-B2 | Inhibitors of AKT activity | MERCK SHARP & DOHME CORP. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8288407-B2 | Substituted naphthyridine compounds as inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120077810-A1 | Inhibitors Of AKT Activity | MERCK SHARP & DOHME LLC | 2012-03-29 | — | — | US | disclosed |
| WO-2012015741-A2 | COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012007345-A2 | SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AND -PYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-19 | — | — | WO | disclosed |
| US-20110288090-A1 | Inhibitors of AKT Activity | MERCK SHARP & DOHME CORP. | 2011-11-24 | — | — | US | disclosed |
| US-20110160183-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2010088177-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
| CN-101600706-A | Inhibitors of AKT activity | MERCK & CO INC (US) | 2009-12-09 | — | — | CN | disclosed |
| WO-2008070041-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070016-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160183-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3CG | AKT1 12/4885AKT2 4/4885EGLN2 3408/4885 |
| US-20130287763-A1 | COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR | IGF1R, IGFBP1, IGFBP2 | AKT1 65/4885AKT2 28/4885EGLN2 1562/4885 |
| US-20120077810-A1 | Inhibitors Of AKT Activity | PIK3CA, PIK3CD, PIK3CB | AKT1 11/4885AKT2 7/4885EGLN2 3016/4885 |
| US-20110288090-A1 | Inhibitors of AKT Activity | PIK3CD, PIK3CA, PIK3CG | AKT1 9/4885AKT2 5/4885EGLN2 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.